46results about How to "Improve exercise tolerance" patented technology

The present invention relates to the identification of a microRNA, miR-208, that induces the expression of β-myosin heavy chain (β-MHC) and represses fast skeletal muscle contractile protein genes. Inhibition of this function is proposed as a treatment for cardiac fibrosis, hypertrophy and/or heart failure, and augmentation of this function can be used to repress slow fiber genes and activate fast fiber genes in the treatment of musculoskeletal disorders.

A treatment apparatus including: a bronchoscope including a flexible shaft having working channel; a transbronchial ablation probe configured to extend from a distal end of the working channel and extend thru a wall of a trachea and into tissue outside of the trachea; and a stabilization element mounted to a distal portion of the flexible shaft, wherein the stabilization element is configured to brace the distal portion against the wall of the trachea while the transbronchial ablation probe is extended through the wall of the trachea.

The present invention provides for methods of treating and preventing cardiac hypertrophy and heart failure. MEF-2 and Class II HDACs have been shown to have a major role in cardiac hypertrophy and heart disease, and inhibition of class II HDAC's has been shown to have a beneficial, anti-hypertrophic effect. The present invention provides a link between MEF-2 and class II HDAC's, a kinase known as PRK. The present invention further demonstrates that inhibitors of PRK inhibit cardiac hypertrophy and heart disease by inhibiting, in part, the fetal cardiac gene expression and cellular reorganization that occurs when MEF-2 dependent transcription is activated.

Provided is the use of a Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease, and particularly the use of the Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.

The invention discloses a wristband watchband with a conductive function, relates to the technical field of smart wristbands, and aims to solve the problem that the watchband is only used for fixing awristband on a wrist and has fewer functions. Key points of the technical scheme are as follows, the watchband comprises a buckle end silica gel watchband and a tongue end silica gel watchband. A buckle is arranged on the buckle end silica gel watchband; a plurality of lock holes are formed in the tongue end silica gel watchband, an electrical stimulation module is arranged in the buckle end silica gel watchband, the electrical stimulation module comprises a signal strip arranged in the length direction of the buckle end silica gel watchband, a circuit board connected with the signal strip and an electrode connected with the circuit board, and the electrode is located at the end, away from the dial plate, of the buckle end silica gel watchband. The signal strip is placed in the buckle endsilica gel watchband, the characteristics of conductivity, waterproofness, stability and the like are achieved, the functionality of the watchband is improved, an electrode is installed at a port ofthe buckle end silica gel watchband, the space of a wristband host is saved, the signal strip embedded in the buckle end silica gel watchband is laid in a snake shape, and the bendable characteristicof the buckle end silica gel watchband is achieved.

The invention discloses a preparation method of a codfish source function low-bitterness oligopeptide. The method comprises the following steps of (1) pretreatment: performing fishskin and fishbone removal on codfish; then, cleanly cleaning the codfish by distilled water; extruding moisture to obtain codfish meat for use; (2) homogenizing: performing primary homogenizing treatment on the codfish meat obtained in the step (1); mixing the codfish meat subjected to the primary homogenizing treatment and distilled water; then, performing secondary homogenizing to obtain codfish meat paste; (3) enzymolysis: firstly, adding bromelain into the codfish meat paste obtained in the step (2) for primary enzymolysis; then, performing enzyme deactivation; then, adding flavourzyme for secondary enzymolysis; performing enzyme deactivation; (4) centrifugation: performing centrifugation on enzymolysis products in the step (3) for 20 to 30 min at 7000 to 8000rpm; (5) spray drying: taking supernate afterthe centrifugation in the step (4); performing spray drying to obtain a finished product. The preparation method is simple; the preparation conditions are mild and can be easily realized; the bitterness of the prepared oligopeptide is low; the utilization rate is low; better flavor is realized; a good sport fatigue resistant effect is achieved.

The invention discloses a Chinese herbal compound for treating idiopathic pulmonary fibrosis as well as a preparation method and application thereof. The Chinese herbal compound is 'wheat flavor lungnourishing soup', which is prepared from twelve traditional Chinese medicine raw materials such as schisandra chinensis, codonopsis pilosula, radix ophiopogonis, fructus perillae, roasted ephedra herb, aster, pericarpium citri reticulatae, ginger processed pinellia, asarum, roasted radix scutellariae, angelica sinensis and roasted licorice roots. A clinical experiment shows that clinical symptomsof an idiopathic pulmonary fibrosis patient, particularly a patient suffering from deficiency of both vital energy and yin, can be obviously improved, the living quality is improved, and the exercisetolerance is enhanced; the Chinese herbal compound is high in safety, and can reduce the lowering rate of the lung functions to a certain extent.

The invention provides diltiazem hydrochloride sustained release tablets. The diltiazem hydrochloride sustained release tablets are prepared from 60 parts of diltiazem hydrochloride, 50-150 parts of sustained release skeleton material and 5-25 parts of lubricating agent by weight. A preparation method of the diltiazem hydrochloride sustained release tablets comprises the steps of material preparing, blending, granulating, blending, tabletting and aluminium-plastic packaging. The diltiazem hydrochloride sustained release tablets and the preparation method have the beneficial effects that the effects of dilating blood vessels, improving myocardial ischemia and reducing blood pressure are achieved by inhibiting internal flow of calcium ions towards coronary vessels and the surroundings of the coronary vessels or peripheral vascular smooth muscle cells; the diltiazem hydrochloride sustained release tablets have the advantages of good medicine stability, convenience in packaging, transportation and storage, and the like; the preparation method is simple and practicable and is suitable for industrial production.

The invention discloses an application of total alkaloids of dendrobium stem in preparation of anti-aging drugs and belongs to the technical field of biomedicine. According to the application, total alkaloids of dendrobium stem are extracted and the content is measured. Through the caenorhabditis elegans anti-aging pharmacodynamics experiment and galactose-caused influence on an aging mouse modeland SAMP8 mouse brain aging protection and mechanism study, it is proved that the total alkaloids of dendrobium stem can improve the learning and memory declining of SAMP8 mice, enhance exercise tolerance, attenuate brain atrophy in SAMP8 mice and reduce the neuronal loss. The results of the experiment are similar to those of the anti-aging drug metformin. The total alkaloids of dendrobium stem have anti-aging effects and the alkaloid action mechanism is related to up-regulation of anti-aging protein Klotho expression, reduction of A beta aggregation and induction of autophagy activity. The experiment results fully prove the anti-aging effects of the total alkaloids of dendrobium stem in anti-aging drugs.

The invention provides a nitric oxide donor traditional Chinese medicine compound preparation. The preparation comprises active raw materials and pharmaceutical acceptable auxiliary materials, whereinthe active raw materials comprise raw materials in parts by mass as follows: 50-100 parts of a first nitric oxide donor plant, 10-30 parts of a second nitric oxide donor plant, 5-20 parts of radix pseudostellariae, 5-20 parts of roasted rhizoma atractylodis macrocephalae, 5-20 parts of rosewood and 1-10 parts of leeches; and the content of nitric oxide donors in the first nitric oxide donor plantis larger than 1500 mg/kg and smaller than or equal to 3500 mg/kg, and the content of nitric oxide donors in the second nitric oxide donor plant is larger than or equal to 1000 mg/kg and smaller thanor equal to 1500 mg/kg. The nitric oxide donor traditional Chinese medicine compound preparation can be used for preventing or treating cardiovascular and cerebrovascular diseases. The invention provides a preparation method and application of the nitric oxide donor traditional Chinese medicine compound preparation. The preparation method is simple, feasible and easy to implement.

The invention provides methods for treating various indications and diseases in a patient in need thereof, wherein the patient has a C825T polymorphism in the G protein beta3 subunit (GNB3), comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.

The invention pertains to the field of traditional Chinese medicine and relates to a pharmaceutical composition for improving the function of skeletal muscle and treating heart failure simultaneously and a preparation method thereof. The pharmaceutical composition aims at the pathogenesis of deficient and weak yang and qi of heart and kidney, fluid retention and blood stagnation of the heart failure and adopts the traditional Chinese medicines of raw membranous milkvetch root, prepared common monkshood daughter root, largehead atractylodes rhizome, white paeony root, Indian buead, common burreed rhizome, zedoary, pepperweed seed, plantain seed, dwarf lilyturf tuber and a pharmaceutically acceptable carrier for preparation. The pharmaceutical composition has the effects of warming yang andqi of heart and kidney, eliminating pathogens from lung and inducing diuresis, the clinical and animal tests prove that the pharmaceutical composition can effectively improve the retention of sodium and water of the patients with the heart failure, liver congestion and even liver cirrhosis due to the congestion; at the same time, the pharmaceutical composition has significant protective effect ofthe damaged function of the skeletal muscle during the heart failure. The pharmaceutical composition is applicable to the patients with the heart failure and the different degrees of fluid retention.The pharmaceutical composition can improve the quality of lives of the patients with the chronic heart failure, further improve the exercise tolerance, increase the 6-minute walking distance and improve the function of the skeletal muscle during the heart failure.

The present invention provides methods of treating and preventing mortality associated with heart failure in an African American patient with hypertension and improving oxygen consumption, quality of life and exercise tolerance by administering a therapeutically effective amount of at least one hydralazine compound and at least one of isosorbide dinitrate and isosorbide mononitrate, and, optionally, one or more compounds, such as, for example, a digitalis, a diuretic compound, or a compound used to treat cardiovascular diseases. In the present invention, the hydralazine compound is preferably hydralazine or a pharmaceutically acceptable salt thereof. Preferred methods of the invention comprise administering hydralazine or a pharmaceutically acceptable salt thereof and isosorbide dinitrate.

Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.

The invention discloses application of a medicine in preparation of drugs for reducing the muscle toxicity of statins. Experimental results show that a heart-nourishing tablet can reduce statins related skeletal muscle injury and improve exercise capacity by enhancing mitochondrial activity, improving oxidative stress and inhibiting myolysis of ApoE-/-mice fed with high fat in exercise training, and the effect is remarkable.

Hypertension is recognized by the medical community at home and abroad as the "most ferocious killer" that threatens the human life, the mortality rate of hypertension is higher than that of any otherdisease, and hypertension seriously affects the human health. Atenolol tablets are administered twice per day, and the blood concentration fluctuates greatly, thereby being necessary to prepare the atenolol tablets into a slow-release preparation. The invention relates to an atenolol slow-release drop pill capable of quickly taking effect and slowly releasing drugs and used for treating hypertension and angina, performing maintenance treatment of myocardial infarction and treating arrhythmia, hyperthyroidism and the like, and a preparation method of the atenolol slow-release drop pill. In order to make up for the deficiencies of the prior art, the invention provides an atenolol slow-release drop pill preparation. The atenolol slow-release drop pill provided by the invention is characterized in that a hydrophobic skeleton capable of slowly releasing drugs and Tween-80 with a solubilizing effect are added on the basis of the existing drop pill technology, the deficiencies of the prior art are effectively overcome, and the atenolol slow-release drop pill has the advantages of uniform drug dispersion, sufficient drug release, long drug release time, reduced patient medication frequency and high bioavailability.